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A Pragmatic Approach Identifies a High 
Rate of Nonalcoholic Fatty Liver Disease 
With Advanced Fibrosis in Diabetes Clinics 
and At-Risk Populations in Primary Care
preya Janubhai patel1,2 , Fabrina Hossain3, leigh ula Horsfall1,2, Xuan Banh2, Kelly lee Hayward2, suzanne Williams3,  
tracey Johnson3, anne Bernard4, nigel neil Brown5, guy lampe5, lyndall Buck5, nivene saad6,7, anthony William Russell7,8, 
patricia Casarolli Valery9 , Katharine margaret irvine2,10, andrew Donald Clouston2, Katherine anne stuart1,  
William Rosenberg11 and elizabeth ellen powell1,2
Noninvasive serum biomarkers (nonalcoholic fatty liver disease fibrosis score [NFS], fibrosis 4 score [FIB-4], or enhanced 
liver fibrosis [ELF] test) are recommended as first-line tools to determine the risk of advanced fibrosis in nonalcoholic fatty 
liver disease. We aimed to assess the utility of a pragmatic approach to screening for clinically significant fibrosis in primary 
care and diabetes clinics. We recruited 252 patients from an endocrine clinic or primary care facility. Anthropometric meas-
urements, ELF test, ultrasound, and liver stiffness measurements (LSMs) were performed. Clinically significant fibrosis 
was defined as LSM ≥8.2 kPa or ELF ≥9.8. A subgroup of patients underwent liver biopsy (n = 48) or had imaging diagnostic 
of cirrhosis (n = 14). Patients were 57.3 ± 12.3 years old with a high prevalence of metabolic syndrome (84.5%), type 2 diabetes 
(82.5%), and body mass index (BMI) ≥40 kg/m2 (21.8%). LSM met quality criteria in 230 (91.3%) patients. NFS and FIB-4 
combined had a high negative predictive value (90.0%) for excluding LSM ≥8.2 kPa. However, 84.1% of patients had inde-
terminate or high NFS or FIB-4 scores requiring further assessment. LSM ≥8.2 kPa and ELF ≥9.8 were present in 31.3% 
and 28.6% of patients, respectively. Following adjustment for age, BMI, sex, and presence of advanced fibrosis, older age was 
independently associated with ELF ≥9.8 (adjusted odds ratio, 1.14; 95% confidence interval, 1.06-1.24), whereas increasing 
BMI was independently associated with LSM ≥8.2 kPa (adjusted odds ratio, 1.15; 95% confidence interval, 1.01-1.30). 
Concordant LSM <8.2 kPa and ELF <9.8 and concordant LSM ≥8.2 kPa and ELF ≥9.8 had a high negative predictive value 
(91.7%) and positive predictive value (95.8%) for excluding and identifying clinically significant fibrosis, respectively. 
Conclusion: Simple scoring tools alone lack accuracy. LSM accuracy is inf luenced by severe obesity, whereas age impacts the 
ELF test. Further studies are required to confirm whether combining LSM and ELF may enhance accuracy and confidence 
in identifying clinically significant fibrosis. (Hepatology Communications 2018;2:893-905)
Nonalcoholic fatty liver disease (NAFLD), esti-mated to affect 25% of the adult population globally,(1) is the most common chronic liver 
disorder seen in primary care.(2) The most import-
ant predictor of mortality in NAFLD is the extent of 
liver fibrosis.(3) In particular, the presence of advanced 
fibrosis (Brunt stage 3-4) is associated with increased 
risks of overall and liver-related mortality.(4,5) These 
patients may benefit from specialist care and sur-
veillance for liver cancer and liver decompensation. 
Reports from transplant registries in the United 
States show that NAFLD is now the second leading 
cause of liver disease(6) and the second most common 
cause of primary liver cancer among adults awaiting 
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hepatocellular carcinoma; IQR, interquartile range; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; NASH, 
nonalcoholic steatohepatitis; NFS, nonalcoholic fatty liver disease fibrosis score; NICE, National Institute for Health and Care Excellence; OR, odds 
ratio; T2DM, type 2 diabetes mellitus.
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liver transplantation.(7) These data highlight the need 
for early identification of patients with NAFLD at 
increased risk of progressive liver disease and cirrho-
sis. Patients with type 2 diabetes mellitus (T2DM) 
and NAFLD are more likely to develop nonalcoholic 
steatohepatitis (NASH), advanced fibrosis/cirrhosis, 
and hepatocellular carcinoma (HCC),(8) and diabetic 
patients have a 2-fold to 3-fold increased risk of mor-
tality from chronic liver disease.(9) Consequently, there 
is increasing interest in the development and imple-
mentation of a NAFLD screening strategy for the 
diabetic population that can be included in clinical 
practice guidelines.(10)
Although NAFLD screening in the community is 
not currently recommended, European clinical prac-
tice guidelines advise that “… the progressive form 
of NAFLD (non-alcoholic steatohepatitis (NASH)), 
particularly when associated with advanced fibrosis, 
should be identified in patients at risk (age >50 years, 
T2DM or metabolic syndrome (MetS)), because of its 
prognostic implications.”(11) Primary care clinicians 
and hospital specialists other than gastroenterologists 
and hepatologists have a key role in identifying patients 
with NAFLD at risk of significant liver disease who 
may require specialist referral for further evaluation or 
who need closer management of metabolic comorbidi-
ties and lifestyle interventions. However, many primary 
care clinicians and hospital specialists underestimate 
the prevalence and do not fully recognize the clinical 
spectrum of NAFLD and how this is assessed.(12),(13)
The European associations for the study of the 
liver, diabetes, and obesity advocate the use of non-
invasive serum biomarkers (NAFLD fibrosis score 
[NFS], fibrosis 4 [FIB-4], or enhanced liver fibrosis 
[ELF] test) for first-line risk stratification, identify-
ing NAFLD cases at low risk of advanced fibrosis/
cirrhosis.(11) The simple scoring systems (NFS and 
FIB-4) combine routine biochemical tests with clini-
cal risk factors for fibrosis, such as age or diabetes, and 
have high negative predictive values for excluding 
advanced fibrosis.(14) The ELF test is a commercial 
panel of markers (tissue inhibitor of matrix metallo-
proteinase, hyaluronic acid, and the aminoterminal 
peptide of procollagen III) focusing on matrix turn-
over that has good  diagnostic accuracy for advanced 
fibrosis in NAFLD.(15) In contrast to the European 
associations, the United Kingdom National Institute 
for Health and Care Excellence (NICE) guidelines 
on the assessment and management of NAFLD rec-
ommend using the ELF test as the first-line test for 
advanced fibrosis in people who have been diagnosed 
with NAFLD.(16) Both guidelines recommend that if 
significant fibrosis cannot be ruled out, patients should 
be referred to a liver clinic for further evaluation, 
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including liver stiffness measurements (LSMs). In 
patients with NAFLD, the LSM has a high negative 
predictive value and a modest positive predictive value 
for detecting advanced fibrosis.(17) This approach, 
however, requires a dedicated complex instrument with 
an XL probe for overweight subjects, an experienced 
operator, and competent interpretation of the results.
The optimal strategy to screen for advanced fibrosis 
in NAFLD remains under discussion, and in Australia, 
there are currently no guidelines for NAFLD manage-
ment. The purpose of this study was to assess the prev-
alence of NAFLD with clinically significant fibrosis in 
T2DM clinics and at-risk populations in primary care. 
In addition, we aimed to assess the utility of a prag-
matic approach to screening for clinically significant 
fibrosis in these populations using noninvasive serum 
biomarkers and LSMs and to determine the extent of 
agreement between these biomarkers.
Patients and Methods
This was a cross-sectional analysis of a prospec-
tive study involving patients identified with NAFLD 
between October 2015 and August 2017.
Case asCeRtainment/stuDy 
eligiBility
The source population included (i) consecutive 
patients scheduled for review in the diabetes clinic 
at Princess Alexandra Hospital, Brisbane, and (ii) all 
patients referred to secondary care from primary care 
due to a history of fatty liver, T2DM, or metabolic syn-
drome during the study period. All eligible patients 
were invited to attend the liver clinic at Princess 
Alexandra Hospital for further clinical assessment.
stuDy population
Patients were eligible to be included in the study if 
they had attended the liver clinic and had a diagno-
sis of NAFLD defined by demonstration of hepatic 
steatosis by liver ultrasound in the presence of meta-
bolic risk factors and the exclusion of significant alco-
hol consumption (≥20 g/day) or other chronic liver 
diseases (including a prior history of alcohol-related 
liver disease).(11) Patients were excluded if they had 
stage 5 chronic kidney disease (estimated glomeru-
lar filtration rate <15 mL/minute), renal replacement 
therapy, history of organ transplant, or if other causes 
of hepatic steatosis were suspected. The derivation of 
the study population is detailed in Supporting Fig. S1. 
We recruited 35% of the entire patient cohort (59.5% 
of the primary care cohort) from a single general 
practice (Inala Primary Care) following screening of 
their at-risk patient population. This general practice 
has expertise in chronic disease and complex diabe-
tes management and delivers an integrated primary– 
secondary care diabetes service. The study clinicians 
(P.P. and E.P.) worked closely with this general prac-
tice to raise awareness about NAFLD in their at-risk 
patient populations.
Informed written consent was obtained from each 
eligible patient, and the protocol was approved by the 
Metro South Health and University of Queensland 
human research ethics committees (HREC/15/
QPAH/301; UQ2015001047).
CliniCal Data
Data were collected prospectively by the study cli-
nician (P.P.). Basic demographic and limited clinical 
information were available for the source population, 
including the NAFLD fibrosis score and/or FIB-4 
tests that were calculated using available clinical and 
laboratory data. Overall risk stratification was per-
formed using the results of the NFS and the FIB-4 
score. Patients were deemed to be at “high risk” of 
advanced fibrosis if either score was high but at “low 
risk” if both their NFS and FIB-4 scores were low. In 
the absence of a high score, “indeterminate risk” was 
assigned if one or both scores were indeterminate.
For patients included in the study, medical history 
was obtained during the initial consultation in the 
liver clinic using a structured questionnaire. Question 
items included self-reported sociodemographic char-
acteristics, history of tobacco use, recreational drug use, 
previously diagnosed liver disease, medical conditions, 
and use of medications. Alcohol intake was assessed 
using a standardized questionnaire and the Alcohol 
Use Disorders Identification Test,(18) as described by 
Patel et al.(19)
Patients underwent a clinical assessment that 
included anthropometric measurements, laboratory 
tests (routine biochemical, hematologic, and serologic 
assays and ELF test), transient elastography, and liver 
ultrasound. In Australia, the ELF test is marketed with 
a recommended cutoff of ≥9.8 for “severe fibrosis”(20) 
(Brunt fibrosis stage ≥F2), and we have previously 
shown that this score reliably identified advanced liver 
fibrosis in patients with chronic liver disease.(21) Body 
patel el al. Hepatology CommuniCations, august 2018
896
mass index (BMI) was adjusted according to ethnicity 
for patients from South Asia (overweight, BMI ≥23 to 
<27.5; class 1 obese, BMI ≥27.5 to 30.0).(22) Metabolic 
syndrome was defined per the International Diabetes 
Federation guidelines.(23)
Transient elastography was performed after a 3-hour 
fast using FibroScan technology (Echosens, Paris, 
France) with the standard M or XL probes in line with 
the manufacturer's instructions. Examinations were 
performed by a trained clinical nurse (with experience 
in performing more than 400 LSMs) and reviewed 
by a hepatologist (K.A.S.) with extensive FibroScan 
experience (more than 2,000 LSMs performed). 
Recommended standard FibroScan operating proce-
dures were followed along with adherence to criteria 
for definition of reliable LSMs as follows: minimum of 
10 valid measurements with a success rate of ≥60% and 
interquartile range (IQR) ≤30% of the final (median) 
result. The XL probe was used when the skin-capsule 
depth was ≥2.5 cm. Although optimal liver stiffness 
cut-off values in NAFLD remain under discussion,(24) 
for the purposes of this study, we used cut-off values of 
8.2 kPa for clinically significant fibrosis,(17) ≥9.5 kPa 
for advanced fibrosis,(25) and >13 kPa to indicate cir-
rhosis(25,26); the same cut-off value was used for both 
probes.(25,26)
Demonstration of steatosis by liver ultrasound was 
determined by the presence of increased hepatic echo-
genicity and beam attenuation, resulting in the renal 
cortex appearing relatively hypoechoic to the liver 
parenchyma, absence of the normal echogenic walls 
of the portal veins, and poor visualization of the dia-
phragm and deep portions of the liver.(27) Evidence 
of cirrhosis or portal hypertension on liver imaging 
was determined by liver surface nodularity or signs of 
portal hypertension, including portal vein dilatation, 
splenomegaly (spleen length >13 cm), portosystemic 
collaterals, and ascites.
liVeR Histology
Patients with clinically significant fibrosis based 
on the FibroScan examination, discordant results of 
investigations for cirrhosis, or interest in participating 
in a clinical therapy trial were invited to undergo liver 
biopsy. Percutaneous liver biopsy was performed under 
ultrasound guidance by an experienced radiologist 
using the Tru-Cut biopsy needle. Liver histology was 
assessed by a single experienced pathologist (A.D.C.) 
who was blinded to the clinical data. Histologic scoring 
was performed according to the system of Kleiner 
et al.(28) Fibrosis was staged from 0 to 4 as follows: stage 
1, zone 3 perisinusoidal only or portal/periportal only; 
stage 2, zone 3 perisinusoidal and portal fibrosis; stage 
3, bridging fibrosis; and stage 4, cirrhosis. Steatosis was 
estimated as a percentage of the parenchyma contain-
ing fat droplets and graded (0-3),(28) and necroinflam-
matory activity was also graded according to severity 
(0-3). NASH was defined by the presence of hepatic 
steatosis with both inflammation and hepatocyte bal-
looning, with or without fibrosis.
Data analysis
Participant sociodemographic and clinical charac-
teristics were described using frequency and percentage 
for categorical variables, mean and SD for continuous 
data normally distributed, and median and IQR for 
non-normally distributed data. Correlation between 
continuous variables was assessed using Spearman's 
rho correlation (nonparametric case). The relation-
ship between two categorical variables was assessed 
using Pearson's chi-squared test or Fisher's exact test, 
as appropriate. The comparison of a continuous vari-
able between two groups was tested using independent 
t tests or Mann-Whitney U tests when the normality 
assumption was not met and one-way analysis of vari-
ance or Kruskal-Wallis test (nonparametric case) when 
comparing more than two groups. Tukey's post-hoc 
tests or Dunn's test (when appropriate) were performed 
when overall significance was demonstrated between 
groups. Univariate logistic regression was performed 
to identify potential predictors of LSM ≥8.2 kPa or 
ELF ≥9.8. All variables with P < 0.2 were included in 
a multiple logistic regression with stepwise selection to 
identify factors influencing the outcome. Odds ratios 
(ORs), adjusted ORs (aORs), and 95% confidence 
intervals (CIs) were reported. All P values were two 
sided, and statistical significance was set at α = 0.05. 
Data analysis was conducted using SPSS Inc. version 
24.0 (StataCorp L.P., College Station, TX; 2013).
Results
souRCe population
A total of 504 patients from a hospital diabetes 
clinic and 571 primary care patients were assessed with 
a NAFLD fibrosis and/or FIB-4 test using available 
laboratory/clinical data. Compared to the diabetes 
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cohort, patients from primary care were less likely to be 
male or have T2DM and had a lower BMI and higher 
serum liver enzyme levels (Supporting Table S1). 
Using published cutoffs,(14) indeterminate or high 
NAFLD fibrosis scores were present in 82.9% of the 
hospital diabetes cohort and 76.9% of the primary care 
cohort. Indeterminate or high FIB-4 scores were pres-
ent in 34.3% and 34.8% of the hospital diabetes cohort 
and primary care cohort, respectively (Supporting 
Table S1). Overall, 77.6% of patients had indetermi-
nate or high scores in at least one test, requiring further 
evaluation to establish the presence or absence of clin-
ically significant fibrosis.
stuDy population
A total of 283 patients accepted the invitation to 
have further clinical assessment in the hepatology 
clinic. Following initial clinical review, 19 patients did 
not meet inclusion criteria (absence of steatosis on liver 
ultrasound examination with no evidence of clinically 
significant liver disease [LSM <8.2], n = 11; excess 
alcohol intake, n = 3; drug-induced steatosis, n = 2; 
other, n = 3) and were excluded from the study and 12 
patients withdrew. The demographic and clinical char-
acteristics of the final cohort (n = 252) are summarized 
in Table 1. Differences between the final cohort and 
source population are detailed in Supporting Tables S1 
and S2. In particular, diabetes was less prevalent in the 
study cohort (P = 0.005), and those included had higher 
BMI (P = 0.001), alanine aminotransferase (ALT) 
(P < 0.001), and aspartate aminotransferase (AST) 
(P < 0.001) values, and fewer patients were stratified 
as low risk overall (P = 0.017). Overall, the mean age 
of subjects included in the study was 57.3 ± 12.3 years 
and 54.4% were male patients. The majority of subjects 
taBle 1. CliniCal anD DemogRapHiC Data FoR tHe Final stuDy CoHoRt
Diabetic Clinic
n = 104 (%)
Primary Care
n = 148 (%)
P Value
Age* 59.5 (52.0-66.0) 58.0 (45.5-68.0) 0.358
Male sex,† n (%) 68 (65.4) 69 (46.6) 0.003
Caucasian ethnicity,† n (%) 86 (82.7) 112 (75.7) 0.181
Metabolic syndrome,† n (%) 99 (95.2) 114 (77.0) <0.001
Type 2 diabetes,‡ n (%) 104 (100) 104 (70.3) <0.001
Body mass index* (kg/m2) 36.0 (30.3-41.7) 32.3 (28.8-37.5) 0.004
Waist* (cm) 123.0 (108.0-134.0) 111.0 (100.3-126.0) <0.001
BMI‡ categorized, n (%) normal weight 2 (2.0) 9 (6.1) 0.049
overweight 19 (18.3) 40 (27.0)
class I obesity 27 (26.0) 45 (30.4)
class II obesity 26 (25.0) 29 (19.6)
≥class III obesity 30 (28.8) 25 (16.9)
Serum liver enzymes* ALT (IU/mL) 30 (21-42) 34 (22-62) 0.015
AST (IU/mL) 21 (15-31) 25 (17-40) 0.009
GGT (IU/mL) 28 (20-50) 36 (20-68) 0.061
Platelet count§ (×109) 244 ± 62 249 ± 65 0.599
Serum albumin* (g/L) 40 (38-42) 42 (40-44) 0.001
LSM range*,‖ 2.6-51.4 2.5-63.9 0.300
LSM ≥8.2 kPa,†,‖ n (%) 28 (31.1) 44 (31.4) 0.960
ELF test range* 7.3-13.0 6.6-12.6 0.947
ELF ≥9.8,† n (%) 27 (26.0) 45 (30.4) 0.442
NFS,‡ n (%) low 4 (3) 44 (29.7) <0.001
indeterminate 66 (63.5) 74 (50.0)
high 34 (32.7) 30 (20.3)
FIB-4 score,† n (%) low 61 (58.7) 89 (60.1) 0.972
indeterminate 38 (36.5) 52 (35.1)
high 5 (4.8) 7 (4.7)
*Continuous data (median [IQR]) analyzed using Mann-Whitney U test; †categorical data analyzed using Pearson's chi-squared test; ‡categorical data analyzed using 
Fisher's exact test; §continuous data (mean ± SD) analyzed using an independent t test; ‖LSM presented for the 230 patients with reliable LSM. 
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(78.6%) were Caucasian, with a mean BMI of 35.1 ± 
8.3 kg/m2 and mean girth of 117.2 ± 19.0 cm. Patients 
had a high prevalence of metabolic syndrome (84.5%) 
and T2DM (82.5%), and more than one fifth of the 
cohort had class 3 obesity or higher (BMI ≥40 kg/m2).
A total of 41.9%, 37.2%, and 47.3% of patients from 
primary care had gamma-glutamyltransferase (GGT), 
AST, and ALT levels above laboratory reference ranges 
(GGT, males ≥55 U/L, females ≥38 U/L; AST, males 
≥35 U/L, females ≥31 U/L; ALT, males ≥45 U/L, 
females ≥34 U/L) compared with 28.8%, 20.4%, and 
26.9% of patients from the diabetes clinic (P = 0.034, 
P = 0.004, and P = 0.001, respectively). Overall, 6% of 
patients had a platelet count <150 × 109/L.
LSM met quality criteria in 230 (91.3%) patients. 
Significantly, almost one quarter (23.6%) of patients 
with severe obesity (BMI ≥40 kg/m2) compared to 
4.6% of patients with BMI <40 kg/m2 had a FibroScan 
that did not meet validity criteria (P < 0.001). Patients 
without a valid LSM were older (P = 0.020), had a 
greater girth (P < 0.001), and had a higher ELF score 
(P = 0.023). Median LSM was 6.1 kPa with a range 
from 2.5 to 63.9 kPa and required use of the XL probe 
in 76.5% of subjects. LSM ≥8.2 kPa, consistent with 
clinically significant fibrosis, was present in 31.1% and 
31.4% of patients from the diabetic clinic and primary 
care cohorts, respectively; 25.6% and 22.9% had an 
LSM ≥9.5 kPa (consistent with advanced fibrosis); and 
18.9% and 14.3% had an LSM >13 kPa (concerning 
for cirrhosis), in the diabetic and primary care cohorts, 
respectively. Fourteen patients (LSM 10.1-63.9 kPa) 
had liver imaging consistent with cirrhosis.
Overall, the mean ELF score was 9.3 ± 1.0, with 
a range from 6.6-13.0. An ELF score ≥9.8, consistent 
with severe fibrosis, was present in 26.0% and 30.4% 
of patients from the diabetic clinic and primary care 
cohorts, respectively. There was a moderate posi-
tive correlation between LSM and ELF test results 
(Spearman's rho = 0.40, P < 0.001; Supporting Fig. S2) 
with concordance between the tests in 76.5% of patients 
with a valid LSM result. The United Kingdom NICE 
guidelines(16) advocate using ELF ≥10.51 to diagnose 
advanced fibrosis. In our study population, 13.1% had 
an ELF score ≥10.51.
The LSM results according to low, indeterminate, 
and high NFS and FIB-4 risk stratification scores are 
illustrated in Fig. 1. In contrast to low NFS scores, low 
FIB-4 scores did not “rule out” subjects with elevated 
LSM ≥8.2 kPa. The combination of a low NFS and 
FIB-4 provided a better negative predictive value (90%) 
than FIB-4 alone for excluding clinically significant 
fibrosis (defined by LSM ≥8.2 kPa). Characteristics of 
the low-risk study population (low score on the FIB-4 
and NFS; n = 40) are summarized in Supporting Table 
S3. In comparison with the indeterminate/high-risk 
cohort, subjects with combined low-risk FIB-4 and 
NFS were younger, had lower prevalence of meta-
bolic syndrome and T2DM, had smaller girth (all 
P < 0.001), and lower BMI (P = 0.002). In contrast, 
serum ALT levels were higher in the low-risk patients 
compared to the indeterminate/high-risk cohort.
FaCtoRs assoCiateD WitH lsm 
≥8.2 Kpa anD/oR elF ≥9.8
Patients with LSM ≥8.2 kPa or ELF ≥9.8 had an 
increased prevalence of T2DM, lower platelet counts, 
and higher BMI, AST, and GGT compared to patients 
with LSM <8.2 kPa or ELF <9.8 (Table 2). Patients 
with LSM ≥8.2 kPa had a greater waist circumference 
(P < 0.001), poorer diabetic control (P = 0.031), and 
higher ALT (P < 0.001), whereas patients with ELF 
≥9.8 were older (P < 0.001). Further assessment com-
paring ELF ≥9.8 and the United Kingdom NICE 
Guideline threshold of ELF ≥10.51 is summarized in 
Supporting Table S4. Patients with a higher ELF score 
were older (P < 0.001), had raised AST and GGT lev-
els (both P < 0.001), lower platelet counts (P = 0.006), 
and higher LSM scores (P < 0.001). A post-hoc analy-
sis did not identify any significant differences between 
ELF ≥9.8 and <10.51 and ELF ≥10.51.
Fig. 1. LSM results according to low, indeterminate, and high 
NFS and FIB-4 risk stratification scores. The horizontal dotted 
line represents an LSM of 8.2.
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Factors associated with LSM ≥8.2 kPa or ELF ≥9.8 
were similar between the primary care and diabetic 
cohorts (Supporting Table S5A,B); however, within 
the primary care cohort, the mean platelet level was 
lower in patients with elevated LSM (P = 0.013) and 
ELF scores (P = 0.004) compared to patients with 
LSM <8.2 kPa or ELF <9.8. This relationship was not 
seen in the diabetic cohort (P = 0.495 and P= 0.318, 
respectively).
Multivariable logistic regression analyses were used 
to identify factors associated with having LSM ≥8.2 
kPa compared to LSM <8.2 kPa, and with having 
ELF ≥9.8 compared to ELF <9.8 (Table 3). All factors 
identified as potentially associated with LSM ≥8.2 kPa 
or ELF ≥9.8 in the univariate analysis (P < 0.2) were 
included in multiple logistic regression analyses with 
stepwise selection. Higher BMI, presence of metabolic 
syndrome, higher AST, higher GGT, and lower platelet 
count were identified as significant determinants of 
LSM ≥8.2 kPa. Further assessment considering BMI 
as categorical (normal plus overweight [<30 kg/m2], 
category 1-2 obesity [31-39.9 kg/m2], and category 3 
obesity and above [≥40 kg/m2]) identified that BMI 
≥40 kg/m2 (aOR, 15.05; 95% CI, 5.08-44.58) but not 
BMI 30-39 kg/m2 (aOR, 1.79; 95% CI, 0.71-4.43) 
when compared to BMI <30 kg/m2 was associated 
with LSM ≥8.2 kPa. Older age, higher BMI, higher 
AST, higher GGT, and lower platelet count were iden-
tified as factors significantly associated with ELF ≥9.8 
compared to ELF <9.8 (Table 3). In this model, when 
age <50 years was compared to age categories 50 to 59, 
60 to 64, and ≥65 years, there was a marked increase 
in the aOR for an association with ELF ≥9.8 (aOR, 
19.42; 95% CI, 3.52-107.19; aOR, 40.02; 95% CI, 
6.70-239.08; and aOR, 113.29, 95% CI, 18.96-676.80, 
respectively).
taBle 2. patient CHaRaCteRistiCs aCCoRDing to lsm anD elF sCoRes
LSM* <8.2
n = 158
LSM* ≥8.2
n = 72
P Value ELF Score <9.8
n = 180
ELF Score ≥9.8
n = 72
P Value
Age† (years) 57.0 (49.0-66.0) 59.5 (52.3-66.0) 0.505 55.0 (45.0-63.0) 65.0 (59.0-72.0) <0.001
BMI† (kg/m2) 31.3 (28.1-35.9) 37.5 (32.9-42.8) <0.001 32.5 (29.3-38.3) 36.0 (30.5-41.4) 0.031
Girth‡ (cm) 109.7 ± 15.3 127.8 ± 17.4 <0.001 117.7 ± 17.5 122.3 ± 18.3 0.055
T2DM,§ n (%) 120 (75.9) 67 (93.1) 0.002 142 (78.9) 66 (91.7) 0.016
HbA1C ≥7%,‖ n (%) 80 (50.6) 48 (66.7) 0.031 102 (56.7) 40 (55.6) 0.872
ALT† (IU/mL) 29 (20-48) 43 (31-64) <0.001 32 (21-52) 33 (22-57) 0.658
AST† (IU/mL) 21 (16-29) 34 (22-47) <0.001 21 (15-32) 31 (18-48) <0.001
GGT† (IU/mL) 27 (19-45) 59 (38-107) <0.001 29 (20-50) 50 (25-97) <0.001
Platelets‡ (× 109) 254 ± 61 232 ± 69 0.016 254 ± 61 229 ± 68 0.004
Albumin† (g/L) 42 (40-44) 41 (38-43) 0.016 41 (39-44) 41 (36-43) 0.155
ELF Score† 8.9 (8.4-9.5) 9.9 (9.3-10.5) <0.001 - - -
ELF ≥ 9.8,‖ n (%) 21 (13.3) 39 (54.2) <0.001 - - -
LSM† (kPa) - - - 5.5 (4.6-7.6) 11.8 (4.2-19.5) <0.001
LSM ≥ 8.2,‖ n (%) - - - 33 (19.4) 39 (65.0) <0.001
*LSM data presented for 230 patients meeting quality criteria; †continuous data (median [IQR]) analyzed using Mann-Whitney U Test; ‡continuous data (mean ± SD) ana-
lyzed using an independent t test; §categorical data analyzed using Fisher’s exact test; ‖categorical data analyzed using Pearson’s chi-squared test.
taBle 3. multiVaRiaBle stepWise logistiC RegRession FoR lsm anD elF sCoRes
LSM <8.2 kPa or ≥8.2 kPa ELF <9.8 or ≥9.8
aOR 95% CI Adjusted P Value aOR 95% CI Adjusted P Value
Age (years) - - - 1.15 1.10-1.20 <0.001
BMI (kg/m2) 1.13 1.07-1.19 <0.001 1.08 1.04-1.13 <0.001
Metabolic syndrome 5.08 1.28-20.18 0.021 - - -
AST (IU/mL) 1.03 1.00-1.05 0.020 1.04 1.02-1.07 0.001
GGT (IU/mL) 1.01 1.00-1.02 0.007 1.01 1.00-1.01 0.056
Platelet count (× 109) 0.99 0.99-1.00 0.013 0.99 0.99-1.00 0.041
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FaCtoRs assoCiateD WitH 
ConCoRDant oR DisCoRDant 
lsm anD elF sCoRes
Patient characteristics according to concordant/
discordant scores are summarized in Table 4. Patients 
with concordant elevated LSM and ELF test were 
more likely to be diabetic (P = 0.005) than patients in 
the other groups. They also had higher AST and GGT 
levels than those patients with concordant low LSM 
and ELF test (P < 0.001). Discordant LSMs and ELF 
scores were present in 54 (23.5%) patients, with no dif-
ference in the rate of discordance between the primary 
care and diabetic cohorts (P = 0.782). Patients with 
ELF ≥9.8 despite LSM <8.2 kPa were significantly 
older when compared to patients with concordant low 
ELF test and LSM as well as patients with low ELF 
test and high LSM (P < 0.001). Patients with ELF ≥9.8 
despite LSM <8.2 kPa were less likely to have elevated 
liver enzymes than patients with concordantly raised 
LSM and ELF test (P < 0.001). In contrast, patients 
with high LSM and low ELF test had a higher BMI 
and waist circumference than those patients with both 
low LSM and ELF test (P = 0.002 and P < 0.001, 
respectively) and those with discordantly raised ELF 
test and low LSM (P < 0.001). Patients with discordant 
raised LSM and low ELF test were more likely to have 
mildly raised ALT and GGT levels when compared to 
patients with discordant raised ELF test and low LSM 
(P = 0.004 and P = 0.008, respectively).
FaCtoRs assoCiateD WitH 
lsm ≥8.2 Kpa anD/oR elF ≥9.8 
in patients WitH aDVanCeD 
FiBRosis ConFiRmeD By 
Histology oR imaging
A total of 48 patients underwent liver biopsy 
(Supporting Table S6), and an additional 14 patients 
had liver imaging diagnostic of cirrhosis. The mean 
liver biopsy length was 17.4 ± 3.2 mm, and mean num-
ber of portal tracts was 15.5 ± 6.1. All patients had 
NASH, and 25 patients (52.1%) had advanced fibro-
sis (Brunt fibrosis stage 3 or 4). Within this subgroup 
of 62 patients, histology or imaging consistent with 
advanced fibrosis was present in 78.8% of patients with 
ELF ≥9.8 and 85.4% with LSM ≥8.2 kPa.
Univariate logistic regression within this subgroup 
identified similar factors to be associated with both 
LSM ≥8.2 kPa and ELF ≥9.8 as in the complete study 
population. The presence of advanced fibrosis (diag-
nosed by histology and/or imaging), BMI, age, and sex 
as variables of clinical relevance were included in a mul-
tivariable logistic regression with stepwise selection. 
Advanced fibrosis (aOR, 51.40; 95% CI, 6.32-418.17) 
and BMI (aOR, 1.15; 95% CI, 1.01-1.30) were found 
taBle 4. patient CHaRaCteRistiCs aCCoRDing to ConCoRDant oR DisCoRDant lsm anD 
elF sCoRes
Low LSM
Low ELF
n = 137
Low LSM
High ELF
n = 21
High LSM
Low ELF
n = 33
High LSM
High ELF
n = 39
P Value
Age* (years) 55.0 ± 12.3 66.0 ± 8.0 50.9 ± 13.2 62.6 ± 8.1 <0.001
Male sex,† n (%) 74 (54.0) 11 (52.4) 19 (57.6) 22 (56.4) 0.973
Caucasian ethnicity,† n (%) 104 (75.9) 13 (61.9) 27 (81.8) 33 (84.6) 0.213
BMI‡ (kg/m2) 31.3 (28.2-35.6) 30.5 (27.1-37.3) 40.5 (34.6-45.3) 36.3 (31.6-42.2) <0.001
Waist circumference* (cm) 110.1 ± 14.6 107.3 ± 19.3 132.2 ± 15.9 124.0 ± 17.8 <0.001
T2DM,§ n (%) 104 (75.9) 16 (76.2) 29 (87.9) 38 (97.4) 0.006
Metabolic syndrome,§ n (%) 107 (78.1) 17 (81.0) 30 (90.9) 38 (97.4) 0.011
eGFR‡ (ml/minute/1.73 m2) 90 (78-90) 81 (63-90) 90 (86-90) 80 (65-90) 0.003
ALT‡ (IU/mL) 30 (21-51) 22 (18-34) 46 (31-61) 38 (33-66) <0.001
AST‡ (IU/mL) 21 (16-30) 24 (15-29) 30 (16-37) 40 (27-66) <0.001
GGT‡ (IU/mL) 26 (20-44) 33 (17-65) 50 (23-79) 72 (47-128) <0.001
Platelet count‡ (× 109) 247 (208-293) 245 (216-303) 243 (210-291) 209 (162-263) 0.019
Albumin‡ (g/L) 42 (40-44) 41 (40-42) 40 (38-43) 41 (39-43) 0.066
HbA1c‡ (%) 7.3 (5.9-8.6) 6.7 (5.8-7.7) 7.7 (6.8-9.0) 7.7 (6.7-9.1) 0.029
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c.
Data only presented for the 230 patients for whom a valid LSM reading was calculated. *Continuous data (mean ± SD) analyzed using a one-way analysis of variance; 
†categorical data analyzed using Pearson's chi-squared test; ‡continuous data (median [IQR]) analyzed using the Kruskal-Wallis test; §categorical data analyzed using 
Fisher's exact test.
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to be significantly associated with LSM ≥8.2 kPa. In 
contrast, age but not BMI was independently associ-
ated with ELF ≥9.8 (aOR, 1.14; 95% CI, 1.06-1.24). 
The aOR for the association between advanced fibrosis 
and ELF ≥9.8 was 3.06 (95% CI, 0.74-12.73), but this 
did not reach statistical significance.
Because BMI did not affect the ELF test result, 
we examined whether combined classification by 
ELF (<9.8 or ≥9.8) and LSM (<8.2 kPa or ≥8.2 kPa) 
increased the accuracy of identifying advanced fibrosis. 
Combining ELF ≥9.8 and LSM ≥8.2 kPa had a positive 
predictive value of 95.8% with a specificity of 95.5% 
for identifying advanced fibrosis (Fig. 2). In contrast, 
when both ELF <9.8 and LSM <8.2 kPa were present, 
there was a negative predictive value of 91.7% with a 
sensitivity of 97.3% for excluding advanced fibrosis.
impaCt on patient 
management
Following review by a hepatologist (E.E.P.), 70 
patients (27.8% of the total cohort) were considered to 
have NAFLD with clinically significant fibrosis based 
on liver histology, imaging, or a combination of non- 
invasive markers and clinical assessment. In 63 of these 
70 patients (90%), this was a new diagnosis of clinically 
significant fibrosis and led to a change in clinical man-
agement, with a recommendation for ongoing review 
in the liver clinic and HCC surveillance.
Discussion
To our knowledge, this is the first prospective 
Australian study to assess a pragmatic approach to 
screening for NAFLD with clinically significant fibro-
sis in T2DM clinics and at-risk populations in primary 
care, using noninvasive serum biomarkers and LSM. 
Overall in our cohort of patients with NAFLD, we 
found a prevalence of clinically significant fibrosis of 
27.8%; this was a new diagnosis in 90% of these cases. 
This is of concern because the extent of liver fibrosis 
is the most important predictor of all-cause mortality 
in NAFLD. The new diagnosis of clinically significant 
fibrosis led to a change in clinical management, with a 
recommendation for ongoing review in the liver clinic 
and HCC surveillance.
In our cohort of “at-risk” subjects, 31.3% had an 
elevated LSM ≥8.2 kPa, suggesting significant liver 
fibrosis. We believe the high rate of clinically signifi-
cant fibrosis in our patient population reflects the high 
prevalence of risk factors for more advanced liver dis-
ease in this cohort, specifically complex T2DM, met-
abolic syndrome, and severe obesity. Among patients 
with diabetes in Hong Kong seen in a hospital set-
ting (n = 1,770) with a median BMI of 26.6 kg/m2, 
17.1% had LSM ≥9.6 kPa using the M probe, whereas 
patients requiring use of the XL probe (n = 114) had 
higher BMI, waist circumference, systolic blood pres-
sure, and hemoglobin A1c and 27.2% had LSM ≥9.3 
kPa.(29) These findings differ from two community- 
based studies of patients with T2DM, where the preva-
lence of significant fibrosis was lower.(25,26) In a French 
community-based diabetic population (n = 669), the 
proportion of patients with LSM ≥8 kPa, 9.6 kPa, and 
13 kPa was 12.7%, 7.3%, and 2.1%, respectively.(25) In 
that study, the mean BMI was 29.6 kg/m2, metabolic 
syndrome was present in 56.2% of patients (com-
pared to 84.5% of our patients), and the XL probe 
was required in only 35% of patients. Similarly, among 
216 subjects from the community with T2DM and 
NAFLD (a subset of a larger population-based study), 
the overall predicted probability of LSM ≥8.0 kPa was 
17.2%.(26)
Even in our considerably obese cohort, FibroScan 
was feasible in 91.3% of patients, similar to the reported 
85% success rate in a mixed overweight and obese dia-
betic cohort.(30) Although obesity is associated with 
Fig. 2. Prevalence of advanced fibrosis (diagnosed by histology 
and/or imaging) according to LSM and ELF concordance.
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LSM failure and unreliability using the M probe, there 
is a higher success rate with the XL probe, which uses 
a lower frequency, a more sensitive ultrasonic trans-
ducer, a deeper focal length, a larger vibration ampli-
tude, and a greater depth of measurement below the 
skin surface.(31) In previous NAFLD studies, LSM 
cut-off values for advanced fibrosis using the M probe 
ranged from 8-12 kPa, with 84%-100% sensitivity 
and 83%-97% specificity.(32) Relatively few published 
data are available using the XL probe, in particular 
the appropriate cut-off values for fibrosis and whether 
severe obesity and steatosis influence the reliability and 
accuracy of these measurements.(33‒38) Importantly, we 
found that, among 41 patients with LSM ≥8.2 kPa (40 
required the XL probe), 85.4% had advanced fibrosis 
or cirrhosis on histology or imaging. In contrast, only 
2 of 18 patients with LSM <8.2 kPa who underwent 
liver biopsy had Brunt fibrosis stage F3 and none had 
cirrhosis. Therefore, our data support studies(29),(39) 
demonstrating that, in this high-risk NAFLD cohort, 
LSM has a valuable role in the assessment of advanced 
fibrosis.
Although the discordance between LSM and his-
tology was low in our liver biopsy group, high BMI 
(>35 kg/m2) has been associated with overestimation 
of fibrosis by LSM with the XL probe compared to 
histologic assessment.(34),(40) In addition, in almost one 
quarter of our patients with BMI ≥40 kg/m2, FibroScan 
did not meet validity criteria, and in our total cohort, 
BMI, particularly ≥40 kg/m2, was independently asso-
ciated with LSM ≥8.2. In view of this, we propose that 
the accuracy and confidence in noninvasive liver fibro-
sis assessment may be improved by combining LSM 
with a serum biomarker of fibrosis that is indepen-
dent of BMI. Among our at-risk patients, 28.6% had 
a serum ELF ≥9.8, the manufacturer's cutoff for severe 
fibrosis. Overall, there was a moderate positive correla-
tion between LSM and ELF test results (P < 0.001, 
Spearman's rho = 0.40), with concordance between the 
two noninvasive biomarkers in 76.5% of cases. Among 
24 patients with both LSM ≥8.2 kPa and ELF ≥9.8 
who proceeded to liver biopsy, 23 had advanced fibrosis 
or cirrhosis on histologic examination and the remain-
ing subject had stage 2 fibrosis. In contrast, only 1 of 12 
Fig. 3. Proposed algorithm to assess for NAFLD and clinically significant fibrosis in at-risk subjects. Boxes shaded in gray represent 
care undertaken prior to hepatology assessment. For patients with evidence of advanced fibrosis/cirrhosis on imaging or biochemical 
abnormalities consistent with advanced fibrosis (e.g., low platelet count, low serum albumin level, AST:ALT reversal) specialist referral 
should be considered. 1Metabolic high-risk factors include age >50 years, presence of diabetes or metabolic syndrome. ^If LSM <8.2 
kPa, consider an alternate cause for ELF ≥9.8 (e.g., extrahepatic fibrosis, increased age). Abbreviation: FBC, full blood count.
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patients with both LSM <8.2 kPa and ELF <9.8 who 
underwent liver biopsy had Brunt fibrosis stage F3. 
Our data support a study in chronic hepatitis B(41) and 
a mixed liver disease etiology cohort(42) that showed 
combining LSM and the ELF test may enhance accu-
racy and confidence in identifying advanced fibrosis. 
However, the small number of patients with histologic 
data in our study limits our ability to draw firm con-
clusions, and further studies are required to clarify the 
benefit of combining these tests.
In the cohort of subjects with a liver biopsy, age (but 
not BMI) was independently associated with ELF 
≥9.8, with a marked increase in the aOR for older 
age categories. The original European liver fibrosis 
test incorporated age, but the algorithm was simpli-
fied by dropping the age variable, without apparent 
loss of diagnostic performance.(43) The median age 
of the original ELF cohort was 43 years (range, 19-
75 years), and the independent patient cohorts used 
to validate simplification of the ELF test had sim-
ilar median ages,(43) whereas the mean age of sub-
jects included in the current NAFLD study was 57.3 
± 12.3 years. This difference in cohort age may have 
impacted diagnostic test performance. Similarly, 
in a study of 400 healthy volunteers, age was found 
to be the most relevant factor influencing the ELF 
score, with a significant increase in ELF score across 
decades from <20 to >60 years.(44) Clearly, further 
analysis of the impact of age on ELF score discrimi-
nation is required.
Our study demonstrates that simple scoring sys-
tems alone lack accuracy and that a sequential algo-
rithm using complementary biomarkers is required 
to appropriately stratify patients according to fibrosis 
risk. Following screening with the NFS, only 20.2% 
of patients had a low risk of advanced fibrosis. In our 
population with T2DM, the utility of the NFS is 
limited by the inclusion of age, BMI, and diabetes, 
leading to a high prevalence (>50%) of indetermi-
nate results. In contrast, screening with the FIB-4 led 
to a low prevalence (<5%) of subjects at high risk of 
advanced fibrosis, likely reflecting the well-preserved 
liver function in patients with NAFLD. However, if 
both the NFS and FIB-4 scores are low, clinically sig-
nificant fibrosis (defined by LSM ≥8.2 kPa) appears to 
be largely excluded (negative predictive value 90.0%). 
Although assessment with FibroScan and ELF was 
performed in the current study in a tertiary hospital 
center, we suggest that these tests may be undertaken 
by primary care clinicians or other specialists to iden-
tify patients with NAFLD and clinically significant 
fibrosis who require hepatology referral for further 
evaluation. Our proposed algorithm for sequential 
use of these complementary biomarkers is summa-
rized in Fig. 3.
Strengths of our study include the prospective 
recruitment of unselected “real-world” subjects from 
both diabetes clinics and primary care facilities, the 
pragmatic use of a combination of readily available 
biomarkers and the use of published cut-off values for 
severe fibrosis. Our study has a number of limitations. 
In particular, liver biopsy was only performed in a sub-
set of patients who were selected based on increased 
likelihood of advanced disease or patient interest in 
participating in clinical therapy trials. In addition to 
diabetes, a high proportion of patients had metabolic 
syndrome and severe obesity, likely contributing to the 
high prevalence of clinically significant fibrosis. As a 
consequence, the study results reflect our source popu-
lations (hospital diabetes clinics and primary care facil-
ities with a high prevalence of complex T2DM and 
metabolic comorbidity), and fibrosis prevalence may be 
different in other populations.
The most concerning result of our study is the high 
prevalence of previously unrecognized severe liver 
fibrosis in these patient populations. The develop-
ment of advanced fibrosis is the major determinant of 
liver-related outcomes as well as predicting overall 
mortality in patients with NAFLD.(4,45) According 
to European and American practice guidelines,(11,46) 
patients with advanced fibrosis or cirrhosis should 
be considered for HCC screening as cirrhosis is an 
important risk factor for HCC and early diagnosis 
improves the applicability and cost effectiveness of 
therapies. However, several studies have identified 
that patients with cirrhosis due to NAFLD are less 
likely to receive surveillance for HCC,(47,48) and this 
may be partly due to failure to recognize cirrhosis 
in clinical practice.(49) Clearly, our data demonstrate 
that diagnosis and risk stratification of patients with 
NAFLD in these high-risk cohorts are important 
unmet clinical needs and warrant proactive strategies 
to ensure recognition. We believe that the use of sim-
ple noninvasive scores followed by use of the ELF test 
and FibroScan may help to resolve the diagnosis of 
advanced fibrosis in the vast majority of patients with 
NAFLD referred from the community or diabetes 
clinics.
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